Vaccines for covid-19 patients

We are currrently developing the protocol for the systematic review on vaccines at the same time we are searching the literature every day and collecting data for candidate vaccines against COVID-19.

Below you can access all the vaccine comparisons where data are available as well as a table with the general characteristics and the risk of bias assessment of each trial. The forest plots, evidence profile and Summary of Findings (SoF) for all the outcomes of interest will be presented soon.

We have identified nine vaccine trials so far, data from these trials are under extraction and will be presented on this page.

The evidence synthesis will be added respectively.

Treatment comparisons

We report below the forest plots for the main treatment comparisons.

Please choose a Treatment Comparison:

Reboot the table and see all comparisons

  • Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp vs Placebo
  • Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp vs Adenovirus type-5-vectored COVID-19 5×10¹° vp
  • Adenovirus type-5-vectored COVID-19 5×10¹° vp vs Placebo

Reboot the table and see all comparisons

Description of primary studies

In this table, we report the main characteristics of the Vaccine RCTs identified.

The link in the column Overall risk of bias will give you access to a complete description of the assessment of each risk of bias domain with supports for judgement. The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column Full description will give you access to the general characteristics of the study.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.

We are in the process of protocol finalization for vaccine trials with a comprehensive list of outcomes specific to vaccine trials.
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Full description
Intervention 1 Intervention 2
NCT04324606
Folegatti PM, Lancet, 2020
Full text
Commentary
Mixed

(Sponsor: University of Oxford )

ChAdOx1 MenACWY RCT Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK N=1077
Some concerns
Details

Full description

NCT04368988
Keech C., N Engl J Med, 2020
Full text
Commentary
Mixed

(Sponsor:Novavax)

2 dose 25μg NVX-D0/21 Placebo RCT Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. N=134
Some concerns
Details

Full description

2 dose 5μg NVX/M1-D0/21 Placebo
2 dose 25μg NVX/M1-D0/21 Placebo
1 dose 25μg NVX/M1+Placebo-D0/21 Placebo
2 dose 25μg NVX-D0/21 2 dose 5μg NVX/M1-D0/21
2 dose 25μg NVX-D0/21 2 dose 25μg NVX/M1-D0/21
2 dose 25μg NVX-D0/21 1 dose 25μg NVX/M1+Placebo-D0/21
2 dose 5μg NVX/M1-D0/21 2 dose 25μg NVX/M1-D0/21
2 dose 5μg NVX/M1-D0/21 1 dose 25μg NVX/M1+Placebo-D0/21
2 dose 25μg NVX/M1-D0/21 1 dose 25μg NVX/M1+Placebo-D0/21
NCT04412538
Pu J, MedRxiv, 2020
Full text
Commentary
Public/non profit

(Sponsor: Chinese Academy of Medical Sciences)

KMS-1 D0/14 Adjuvant RCT Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China. N=96
Some concerns
Details

Full description

KMS-1 D0/28 Adjuvant
NCT04436276
Sadoff J, MedRxiv, 2020
Full text
Commentary
Mixed

(Sponsor: Janssen Vaccines & Prevention B.V. )

Ad26.COV2.S 5x10^10vp 18-55y Placebo RCT Healthy SARS-CoV-2 nucleic acid negative adults 18-55 years old and elderly >65 years old in multiple centres in Belgium and the US N=380
High
Details

Full description

Ad26.COV2.S >65y Placebo
NCT04368728
Walsh E, MedRxiv, 2020
Full text
Commentary
Private (Sponsor: BioNTech) BNT162b1 D1/21 18-55y Placebo RCT Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA N=60
Some concerns
Details

Full description

BNT162b1 D1/21 >65y Placebo
BNT162b2 D1/21 18-55y Placebo
BNT162b2 D1/21 >65y Placebo
ChiCTR2000031809
Xia S, JAMA, 2020
Full text
Commentary
Mixed

(Sponsor: China National Biotec Group &

Wuhan Institute of Biological Products )

Inactivated 2.5μg-D0/28/56 Adjuvant RCT Healthy adults, aged 18 to 59 years, without history of SARS-CoV (via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test) N=96
Low
Details

Full description

Inactivated 5μg-D0/28/56 Adjuvant
Inactivated 10μg-D0/28/56 Adjuvant
Inactivated 2.5μg-D0/28/56 Inactivated 5μg-D0/28/56
Inactivated 2.5μg-D0/28/56 Inactivated 10μg-D0/28/56
Inactivated 5μg-D0/28/56 Inactivated 10μg-D0/28/56
Inactivated 5μg-D0/14 Adjuvant
Inactivated 5μg-D0/21 Adjuvant
ChiCTR2000032459
Xia S, Lancet Infect Dis, 2020
Full text
Commentary
Mixed

(Sponsor: Henan Provincial Center for Disease Control and Prevention)

Inactivated SARS-CoV-2 vaccine, 1-dose 8 ?g, Day 0 Aluminum hydroxide adjuvant RCT Healthy SARS-CoV-2 serology negative adults 18-59 years old and ?60 years old in a single centre in China N=112
Some concerns
Details

Full description

Inactivated SARS-CoV-2 vaccine, 2-dose 4 ?g, Days 0/14 Aluminum hydroxide adjuvant
Inactivated SARS-CoV-2 vaccine, 2-dose 4 ?g, Days 0/21 Aluminum hydroxide adjuvant
Inactivated SARS-CoV-2 vaccine, 2-dose 4 ?g, Days 0/28 Aluminum hydroxide adjuvant
NCT04352608
Zhang Y, MedRxiv, 2020
Full text
Commentary
Mixed

(Sponsor: Sinovac Biotech Co., Ltd)

Corona Vac 3μg-D0/14 Adjuvant RCT Healthy volunteers aged 18-59, negative in COVID-19 serum antibodies and SARS CoV-2 infection-free, in a single centre in China. N=300
Some concerns
Details

Full description

Corona Vac 6μg-D0/14 Adjuvant
Corona Vac 3μg-D0/14 Corona Vac 6μg-D0/14
Corona Vac 3μg-D0/28 Adjuvant
Corona Vac 6μg-D0/28 Adjuvant
Corona Vac 3μg-D0/28 Corona Vac 6μg-D0/28
NCT04341389
Zhu F, The Lancet, 2020
Full text
Commentary
Commentary
Mixed(National Science and Technology Major Project, CanSino Biologics.) Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp Placebo RCT Healthy adult volunteers with HIV-negative and SARS-CoV-2 infection-free in a single centre in China. N=508
Some concerns
Details

Full description

Adenovirus type-5-vectored COVID-19 5×10¹° vp Placebo
Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp Adenovirus type-5-vectored COVID-19 5×10¹° vp